A Phase 1 clinical trial of CBA-1535
Latest Information Update: 18 Dec 2023
At a glance
- Drugs CBA 1535 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
Most Recent Events
- 14 Dec 2023 According to a Chiome Bioscience media release, The company had previously planned to start the second part in parallel with the first part but has now changed its plan to start the second part after confirming the efficacy signal in the first part. The second part will begin in 2024.
- 14 Dec 2023 According to a Chiome Bioscience media release, the company submitted a clinical trial plan notification to the PMDA in February 2022
- 11 May 2023 According to a Chiome Bioscience media release, the first part of this study is ongoing.